Business Context and Reporting Period
Company: Myomo, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 24, 2023
Event: Entry into a Material Definitive Agreement regarding a registered public offering of common stock and pre-funded warrants.
Key Financial Metrics and Transaction Details
- Securities Issued: 5,413,334 shares of Common Stock and pre-funded warrants to purchase 1,920,000 shares.
- Offering Prices: $0.60 per Share; $0.5999 per Pre-Funded Warrant.
- Gross Proceeds: Expected $4.4 million (before fees and expenses).
- Placement Agent Fees: 6% of aggregate gross proceeds, plus a $10,000 non-accountable expense allowance and up to $50,000 in accountable legal expenses.
- Use of Proceeds: General corporate purposes, including working capital, capital expenditures, R&D, and sales/marketing. Potential future use includes headcount expansion and inventory procurement contingent on CMS classification.
Material Changes and Restrictions
This filing does not report changes to historical revenue, profit, or cash flow metrics. The material change is the capital raise and associated contractual restrictions:
- 90-Day Lock-Up: The Company is restricted from issuing additional common stock or equivalents (with limited exceptions) for 90 days post-closing.
- 12-Month Restrictions: Prohibition on Variable Rate Transactions and reducing the exercise price of existing common stock equivalents for 12 months post-closing.
- Ownership Caps: Pre-Funded Warrant exercise is limited to prevent holders from owning more than 4.99% (or 9.99% with notice) of outstanding shares immediately after exercise.
Guidance, Outlook, and Risks
Outlook: Management intends to utilize proceeds to support operations and potentially scale patient servicing if the Centers for Medicare and Medicaid Services (CMS) finalizes the Company's classification as a brace and publishes a fee before year-end.
Risks and Contingencies:
- Regulatory Contingency: Operational scaling plans are contingent on CMS finalizing a fee schedule for the Company's product.
- Dilution: The issuance of new shares and warrants will increase the total share count, potentially diluting existing shareholders.
- Closing Conditions: The transaction is subject to customary closing conditions, with an expected closing date of August 29, 2023.
Investor Verification Checklist
- Verify the final closing date and actual gross proceeds received versus the expected $4.4 million.
- Confirm the status of the CMS classification and fee schedule announcement expected before the end of the year.
- Review the full Placement Agency Agreement (Exhibit 10.1) for additional terms regarding the 6% fee and expense allowances.
- Monitor the Company's compliance with the 90-day and 12-month issuance restrictions.
- Check the final prospectus supplement filed on August 28, 2023, for complete offering details.